Islet Transplantation in Type 1 Diabetes



Status:Archived
Conditions:Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:Any
Updated:7/1/2011

Use our guide to learn which trials are right for you!


Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta
cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to
determine the safety and effectiveness of islet transplantation, combined with
immunosuppressive medications, for treating type 1 diabetes in individuals experiencing
hypoglycemia unawareness and severe hypoglycemic episodes.


Type 1 diabetes is commonly treated with the administration of insulin, either by multiple
insulin injections or by a continuous supply of insulin through a wearable pump. Insulin
therapy allows long-term survival in individuals with type 1 diabetes; however, it does not
guarantee constant normal blood sugar control. Because of this, long-term type 1 diabetic
survivors often develop vascular complications, such as diabetic retinopathy, an eye disease
that can cause poor vision and blindness, and diabetic nephropathy, a kidney disease that
can lead to kidney failure. Some individuals with type 1 diabetes develop hypoglycemia
unawareness, a life-threatening condition that is not easily treatable with medication and
is characterized by reduced or absent warning signals for hypoglycemia. For such
individuals, transplantation of pancreatic islets is a possible treatment option.
Unfortunately, insulin independence among islet transplant recipients tends to decline over
time. New strategies aimed at promoting engraftment of transplanted islets are needed to
improve the clinical outcomes associated with this procedure. The purpose of this study is
determine the safety and efficacy of islet transplantation, when combined with an
immunosuppressive medication regimen, for treating type 1 diabetes in individuals
experiencing hypoglycemia unawareness and severe hypoglycemic episodes. This study will also
seek to improve the understanding of determinants of success and failure of islet
transplants for type 1 diabetes.

Eligible participants will be randomly assigned to this study or a site-specific Phase 2
islet transplantation study. Participants in this study will receive up to three separate
islet transplants and a regimen of immunosuppressive medications consisting of antithymocyte
globulin (ATG), sirolimus, and low-dose tacrolimus. They will begin receiving ATG and
sirolimus 2 days prior to the first islet transplant. ATG will continue to be given until
Day 2 post-transplant, and sirolimus will be given for the duration of the study. On Day 1
post-transplant, participants will receive tacrolimus, which will also be taken for the
duration of the study. Etanercept will be taken on the day of transplant and Days 3, 7, and
10 post-transplant.

Transplantations will involve an inpatient hospital stay and infusion of islets into a
branch of the portal vein. Participants who do not achieve or maintain insulin independence
by Day 75 post-transplant will be considered for a second islet transplant. Participants who
remain dependent on insulin for longer than 1 month after the second transplant and who show
partial graft function will be considered for a third islet transplant. Daclizumab or
basiliximab will be used in place of ATG for the second and third transplants, if they are
necessary. Participants who do not meet the criteria for a subsequent transplant and do not
have a functioning graft will enter a reduced follow-up period.

There will be up to 19 study visits following each transplant. A physical exam, review of
adverse events, and blood collection will occur at most visits. A chest x-ray, abdominal
ultrasound, electrocardiogram, quality of life questionnaires, urine collection, and
glomerular filtrating rate (GFR) testing will occur at some visits. Participants will also
test their own blood glucose levels at least five times per day throughout the study. A
24-month follow-up period will take place after the participant's last transplant.


We found this trial at
7
sites
201 East Huron Street
Chicago, Illinois 60611
(847) 491-3741
Northwestern University Northwestern is recognized both nationally and internationally for the quality of its educational...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1853 West Polk Street
Chicago, Illinois 60612
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2450 Riverside Avenue
Minneapolis, Minnesota 55455
(612) 273-3000
University of Minnesota Medical Center Improving patients' lives drives the innovation that makes University of...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
3400 Spruce St
Philadelphia, Pennsylvania 19104
 (215) 662-4000
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
1400 NW 12th Ave
Miami, Florida 33136
(305) 689-5511
University of Miami Hospital The University of Miami changed the face of modern health care...
?
mi
from
Miami, FL
Click here to add this to my saved trials
500 Parnassus Ave
San Francisco, California 94143
(415) 476-9000
University of California at San Francisco (UCSF) The leading university exclusively focused on health, UC...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials